For the Inventor, By the Inventor

Enter assignee name

Palo Alto, CA, United States of America

Affymax, Inc.

Calculating rank

USPTO Granted Patents = 23

% Expired Patents = 69.6

EPO Patents = 2

Forward Citations = 306

Loading Chart...

Loading Chart...

43 inventors (with patents filed for the assignee):

Christopher P Holmes (11 out of 31 patents)

Qun Yin (10 out of 30 patents)

Peter J Schatz (8 out of 31 patents)

4. David Tumelty (8 out of 10 patents)

5. Genet Zemede (6 out of 14 patents)

6. Palani Balu (6 out of 14 patents)

7. Guy Lalonde (6 out of 10 patents)

8. Anne-Marie Duliege (4 out of 4 patents)

9. Richard Stead (4 out of 4 patents)

10. Kerstin Leuther (4 out of 4 patents)

11. Robert Barnett Naso (4 out of 4 patents)

12. Balu Palani (4 out of 4 patents)

13. Kathryn Wynne Woodburn (4 out of 7 patents)

14. William J Dower (2 out of 77 patents)

15. Steven E Cwirla (2 out of 39 patents)

23 patents: Sort by Forward Citations

1. 8729030 - Peptides that bind to the erythropoietin receptor (2014-05-20),

2. 8592365 - Spacer moiety for poly(ethylene glycol) modified peptide based compounds (2013-11-26),

3. 8324159 - Erythropoietin receptor peptide formulations and uses (2012-12-04),

4. 8304391 - Peptides that bind to the erythropoietin receptor (2012-11-06),

5. 8106154 - Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules (2012-01-31),

6. 7919461 - Erythropoietin receptor peptide formulations and uses (2011-04-05),

7. 7919118 - Spacer moiety for poly (ethylene glycol) modified peptide based compounds (2011-04-05),

8. 7906485 - Erythropoietin receptor peptide formulations and uses (2011-03-15),

9. 7855175 - Peptides that bind to the erythropoietin receptor (2010-12-21),

10. 7553617 - Peptide library and screening systems (2009-06-30),

11. 7550433 - Erythropoietin receptor peptide formulations and uses (2009-06-23),

12. 7528104 - Peptides that bind to the erythropoietin receptor (2009-05-05),

13. 7482433 - Peptides and compounds that bind to the IL-5 receptor (2009-01-27),

14. 7459522 - Peptide dimers as agonists of the erythropoietin (EPO) receptor, and associated methods of synthesis and use (2008-12-02),

15. 7414105 - Peptides that bind to the erythropoietin receptor (2008-08-19),

Company Overview

Affymax, Inc. is a biopharmaceutical company based in Palo Alto, California, specializing in the development of innovative therapies for patients with chronic kidney disease. The company focuses on advancing its proprietary technology platform to create novel treatments that enhance the quality of life for patients requiring dialysis. With a commitment to research and development, Affymax aims to address unmet medical needs through its unique approach to drug formulation and delivery, contributing to the evolving landscape of renal care.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

23 Patents

#77 in Palo Alto, CA

#3,424 in California

#14,450 in US

#27,736 in the World

Palo Alto, CA, United States of America

Affymax, Inc.

Forward Citations = 306

43 inventors:

Christopher P Holmes (11 out of 31 patents)

Qun Yin (10 out of 30 patents)

Peter J Schatz (8 out of 31 patents)

4. David Tumelty (8 out of 10 patents)

5. Genet Zemede (6 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Affymax, Inc.. Retrieved from https://idiyas.com/company/affymax

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…